Latest From Taragenyx Ltd.
Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging biopharma, medtech, and diagnostic life science companies that have received venture funding.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.
Brief profiles of these recently formed companies: Neurotrack, Podimetrics, scPharmaceuticals, and Taragenyx.
- Implantable Devices
- Therapeutic Areas
- Dental & Oral Products
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- Taragenyx Ltd.
- Senior Management
Iain McDougall, PhD, CEO
Raman Bedi, CMO
Deepak Basra, CBO
- Contact Info
Phone: (141) 418 9637
Entrepreneurial Spark, Caledonia House
Glasgow, Scotland, G5 0US
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.